What is ARTV's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.34B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ARTV?

P/E (TTM) is n/a and 52-week range is $2.71 to $14.53 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ARTV figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ARTV?

The company profile lists net income (TTM) near $-167M, EPS (TTM) near $-3.43 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Artiva Biotherapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 48.6M shares outstanding, ISIN US04317A1079 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Artiva Biotherapeutics Inc

$ARTV

Health Care · Biotechnology

Run Scenarios

$6.94

+2.06%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. The company is headquartered in San Diego, California and currently employs 104 full-time employees. The company went IPO on 2024-07-19. The firm is focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers. Its product candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen and ready to ship to a patient's treatment location. Its lead product candidate, AlloNK, is being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs) in patients with autoimmune diseases and cancers, such as systemic lupus erythematosus (SLE), lupus nephritis (LN), RA, PV, the ANCA-associated vasculitis subtypes GPA/MPA, and B-NHL. AlloNK is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted mAbs in an ongoing Phase I/Ib trial in SLE with or without LN and a basket investigator-initiated trial (IIT) in multiple autoimmune indications.

Employees

104

Website

www.artivabio.com/

IPO

2024-07-19

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)